淀粉样蛋白PET与tau-PET诊断价值的头对头比较
该研究在136例记忆门诊患者中随机分配 amyloid-PET 与 tau-PET 的呈现顺序,由两名神经科医生独立评估病因诊断与诊断信心。两种PET作为首项检查时均使约28%病例诊断改变、诊断信心提升约18%–19%;阴性amyloid-PET对诊断的影响强于阴性tau-PET。作为第二项检查时两者均进一步提升诊断信心。
要点
- amyloid-PET与tau-PET作为首项检查均显著改变病因诊断并提升诊断信心。
- 阴性amyloid-PET对诊断的影响强于阴性tau-PET(p=0.014)。
- 作为第二项检查,两者仍进一步提升诊断信心,但诊断改变未达统计学显著。
核心结论
- amyloid-PET与tau-PET对诊断和诊断信心的影响相似,但阴性amyloid-PET对诊断的影响强于阴性tau-PET。
- 将任一PET作为第二项检查可进一步提升诊断信心。
研究设计与样本
- 研究纳入136例记忆门诊患者,临床报告随机分配至AMY-TAU或TAU-AMY两条诊断路径。
- 两名神经科医生采用平衡随机设计独立评估报告,在基线、第一项PET后及剩余PET后三次给出病因诊断与诊断信心(50–100%)。
主要发现
- amyloid-PET与tau-PET作为首项检查时,分别使28%(p=0.006)和28%(p<0.001)的病例病因诊断改变。
- 作为首项检查时,诊断信心分别提升18%(p<0.001)和19%(p<0.001),两项检查间无差异(p>0.05)。
- 阴性amyloid-PET对诊断的影响强于阴性tau-PET(p=0.014)。
- 作为第二项检查时,amyloid-PET与tau-PET分别使6%(p=0.077)和9%(p=0.149)的病例诊断进一步改变。
- 作为第二项检查时,诊断信心分别提升4%(p<0.001)和5%(p<0.001),两项检查间无差异(p>0.05)。
临床怎么用
- 在记忆门诊中,amyloid-PET与tau-PET均可作为首项检查显著影响病因诊断与诊断信心。
- 阴性amyloid-PET对排除AD的诊断影响更强,可优先考虑用于需要排除AD的场景。
- 将任一PET作为第二项检查可进一步提升诊断信心,支持联合使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Assess the individual and combined diagnostic value of amyloid-PET and tau-PET in a memory clinic population. METHODS: Clinical reports of 136 patients were randomly assigned to two diagnostic pathways: AMY-TAU, amyloid-PET is presented before tau-PET; and TAU-AMY, tau-PET is presented before amyloid-PET. Two neurologists independently assessed all reports with a balanced randomized design, and expressed etiological diagnosis and diagnostic confidence (50-100%) three times: (i) at baseline based on the routine diagnostic workup, (ii) after the first exam (amyloid-PET for the AMY-TAU pathway, and tau-PET for the TAU-AMY pathway), and (iii) after the remaining exam. The main outcomes were changes in diagnosis (from AD to non-AD or vice versa) and in diagnostic confidence. RESULTS: Amyloid-PET and tau-PET, when presented as the first exam, resulted in a change of etiological diagnosis in 28% (p = 0.006) and 28% (p < 0.001) of cases, and diagnostic confidence increased by 18% (p < 0.001) and 19% (p < 0.001) respectively, with no differences between exams (p > 0.05). We observed a stronger impact of a negative amyloid-PET versus a negative tau-PET (p = 0.014). When added as the second exam, amyloid-PET and tau-PET resulted in a further change in etiological diagnosis in 6% (p = 0.077) and 9% (p = 0.149) of cases, and diagnostic confidence increased by 4% (p < 0.001) and 5% (p < 0.001) respectively, with no differences between exams (p > 0.05). CONCLUSION: Amyloid-PET and tau-PET significantly impacted diagnosis and diagnostic confidence in a similar way, although a negative amyloid-PET has a stronger impact on diagnosis than a negative tau-PET. Adding either of the two as second exam further improved diagnostic confidence. TRIAL NUMBER: PB 2016-01346.
引用
- Altomare D, Caprioglio C, Assal F, et al. Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison. Eur J Nucl Med Mol Imaging. 2021. PMID: 33638661. doi:10.1007/s00259-021-05246-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。